Literature DB >> 9087482

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

K Venkateswarlu1, M Taylor, N J Manning, M G Rinaldi, S L Kelly.   

Abstract

Eleven isolates of Cryptococcus neoformans were investigated to determine the biochemical basis of their tolerance to fluconazole. The MICs of fluconazole for three isolates with low-level resistance were 3- to 6-fold higher than those for sensitive isolates, while the MICs for four isolates with high-level resistance were 100- to 200-fold higher than those for sensitive isolates. The level of ergosterol present in the isolates varied, and those which had relatively low levels of ergosterol were resistant to amphotericin B. Changes in the affinity of the target enzyme (sterol 14alpha-demethylase) and decreases in the cellular content of fluconazole seemed to be responsible for the resistance in isolates with low-level and high-level resistance, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087482      PMCID: PMC163787     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.

Authors:  P F Watson; M E Rose; S W Ellis; H England; S L Kelly
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

2.  Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

Authors:  T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 3.  Molecular genetic analysis of azole antifungal mode of action.

Authors:  S L Kelly; A Arnoldi; D E Kelly
Journal:  Biochem Soc Trans       Date:  1993-11       Impact factor: 5.407

4.  Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient.

Authors:  S L Kelly; D C Lamb; M Taylor; A J Corran; B C Baldwin; W G Powderly
Journal:  FEMS Microbiol Lett       Date:  1994-09-15       Impact factor: 2.742

Review 5.  Biochemical basis for the activity and selectivity of oral antifungal drugs.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene
Journal:  Br J Clin Pract Suppl       Date:  1990-09

Review 6.  Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene; G Willemsens; D Bellens; I Roels; H Moereels; P A Janssen
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

7.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

8.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

9.  Altered P450 activity associated with direct selection for fungal azole resistance.

Authors:  T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal:  FEBS Lett       Date:  1995-10-30       Impact factor: 4.124

10.  Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; D E Kelly
Journal:  Biochem Biophys Res Commun       Date:  1995-02-27       Impact factor: 3.575

View more
  24 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

Review 4.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

5.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

Review 6.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

7.  Heteroresistance of Cryptococcus gattii to fluconazole.

Authors:  A Varma; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

8.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.

Authors:  J R Thompson; C M Douglas; W Li; C K Jue; B Pramanik; X Yuan; T H Rude; D L Toffaletti; J R Perfect; M Kurtz
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.